Business
Operational update on Strategic Investments
Operational update on Strategic Investments.
About this update from Truetide Plc
[{"type":"text","content":"\n \nRNS Number : 3607B Braveheart Investment Group plc 30 January 2020 \n\n30 January 2020\n \nBraveheart Investment Group plc (\"Braveheart\" or the \"Group\")\nOperational update on Strategic Investments\nBraveheart (AIM:BRH), the fund management and strategic investment group, is pleased to provide an operational update on its strategic investments.\nParaytec Limited (\"Paraytec\") (holding 100%)\nThe second round of end user trials are underway on Paraytec's Innovate UK funded R&D project (\"NEXUS\"), which is developing instrumentation for measuring protein aggregation in biopharmaceuticals. Trials have already been conducted with Fujifilm Diosynth and members of Paraytec's scientific team will visit GlaxoSmithKline and Medimmune over the coming weeks. Protein aggregates are an impurity that must be controlled and must stay within product specifications, so measurement is essential to ensure that products containing protein aggregates meet the regulatory requirements. \nPharm 2 Farm Limited (\"P2F\") (holding 51.72%)\nP2F's team attended Europe's premiere turf management show, BTME in Harrogate, earlier this month and received significant interest from across the industry. Turf management in golf and sports surfaces is a highly technical and suppliers and managers of turf are continually looking for the latest innovations to keep their turf in the best possible condition throughout the year.\nThis month, the company produced a batch of silicon micronutrient for shipment to customers in the Australian hydroponics market. Silicon is important because it improves nutrient uptake, strengthens plants against disease, drought and other plant stresses. \n \nAll of P2F's coated particles have improved bioavailability over traditional plant feeds, resulting in stronger plants that grow more quickly and produce higher yields. End users are currently focussed on high value crops in the horticultural and pharmaceutical markets, including the cultivation of medicinal cannabis.\n \nKirkstall Limited (\"Kirkstall\") (holding 64.67%)\nKirkstall has recently appointed new distributors in South Korea and China. The distributors are currently undertaking product training and their promotional plans for 2020 are being finalised.\nKirkstall presented at the recent joint Integrated Biological Imaging Network/3DbioNet me...